These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32486461)

  • 1. A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma.
    Macias RIR; Muñoz-Bellvís L; Sánchez-Martín A; Arretxe E; Martínez-Arranz I; Lapitz A; Gutiérrez ML; La Casta A; Alonso C; González LM; Avila MA; Martinez-Chantar ML; Castro RE; Bujanda L; Banales JM; Marin JJG
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach.
    Le Large TYS; Meijer LL; Paleckyte R; Boyd LNC; Kok B; Wurdinger T; Schelfhorst T; Piersma SR; Pham TV; van Grieken NCT; Zonderhuis BM; Daams F; van Laarhoven HWM; Bijlsma MF; Jimenez CR; Giovannetti E; Kazemier G
    Oncologist; 2020 Apr; 25(4):e634-e643. PubMed ID: 31943574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Metabolite Biomarkers for Pancreatic Tumors: Neuroendocrine and Pancreatic Ductal Adenocarcinomas-A Preliminary Study.
    Skubisz K; Dąbkowski K; Samborowska E; Starzyńska T; Deskur A; Ambrozkiewicz F; Karczmarski J; Radkiewicz M; Kusnierz K; Kos-Kudła B; Sulikowski T; Cybula P; Paziewska A
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel Approach.
    Boyd LNC; Ali M; Kam L; Puik JR; Rodrigues SMF; Zwart ES; Daams F; Zonderhuis BM; Meijer LL; Le Large TYS; Giovannetti E; van Laarhoven HWM; Kazemier G
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomic Profiling of Plasma from Melioidosis Patients Using UHPLC-QTOF MS Reveals Novel Biomarkers for Diagnosis.
    Lau SK; Lee KC; Lo GC; Ding VS; Chow WN; Ke TY; Curreem SO; To KK; Ho DT; Sridhar S; Wong SC; Chan JF; Hung IF; Sze KH; Lam CW; Yuen KY; Woo PC
    Int J Mol Sci; 2016 Feb; 17(3):307. PubMed ID: 26927094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma.
    Cao YY; Guo K; Zhao R; Li Y; Lv XJ; Lu ZP; Tian L; Ren S; Wang ZQ
    Digit Health; 2023; 9():20552076231179007. PubMed ID: 37312938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment.
    Gkountakos A; Martelli FM; Silvestris N; Bevere M; De Bellis M; Alaimo L; Sapuppo E; Masetto F; Mombello A; Simbolo M; Bariani E; Milella M; Fassan M; Scarpa A; Luchini C
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors.
    Meijer LL; Puik JR; Le Large TYS; Heger M; Dijk F; Funel N; Wurdinger T; Garajová I; van Grieken NCT; van de Wiel MA; Giovannetti E; Kazemier G
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31443224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma.
    Cao Y; Zhao R; Guo K; Ren S; Zhang Y; Lu Z; Tian L; Li T; Chen X; Wang Z
    Front Oncol; 2021; 11():744667. PubMed ID: 35127469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.
    Banales JM; Iñarrairaegui M; Arbelaiz A; Milkiewicz P; Muntané J; Muñoz-Bellvis L; La Casta A; Gonzalez LM; Arretxe E; Alonso C; Martínez-Arranz I; Lapitz A; Santos-Laso A; Avila MA; Martínez-Chantar ML; Bujanda L; Marin JJG; Sangro B; Macias RIR
    Hepatology; 2019 Aug; 70(2):547-562. PubMed ID: 30325540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.
    Itoi T; Sugimoto M; Umeda J; Sofuni A; Tsuchiya T; Tsuji S; Tanaka R; Tonozuka R; Honjo M; Moriyasu F; Kasuya K; Nagakawa Y; Abe Y; Takano K; Kawachi S; Shimazu M; Soga T; Tomita M; Sunamura M
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28375170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
    Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
    Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
    He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
    Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
    Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
    Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
    Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
    LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
    BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrimination of pancreatic cancer and pancreatitis by LC-MS metabolomics.
    Lindahl A; Heuchel R; Forshed J; Lehtiö J; Löhr M; Nordström A
    Metabolomics; 2017; 13(5):61. PubMed ID: 28413374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Metabolomics as a Complementary Omic Approach to Implement Risk Criteria for First-Degree Relatives of Gastric Cancer Patients.
    Corona G; Cannizzaro R; Miolo G; Caggiari L; De Zorzi M; Repetto O; Steffan A; De Re V
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.